About Gentronix
Gentronix is a company based in Alderley Edge (United Kingdom) founded in 1999 was acquired by Scantox in September 2024. Gentronix has raised $3.84 million across 3 funding rounds from investors including Mercia, Scantox and NVM Private Equity. The company has 1 employees as of December 31, 2015. Gentronix offers products and services including Genetic Toxicology Testing, GLP Genotoxicity Services, Skin Toxicology Services, and Flow Cytometry Services. Gentronix operates in a competitive market with competitors including Jade Bioscience, Tigermed, Shanghai Yaocheng Health Technology, ReveraGen and Aquila BioMedical, among others.
- Headquarter Alderley Edge, United Kingdom
- Employees 1 as on 31 Dec, 2015
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Gentronix Limited
- Date of Incorporation 15 Jul, 1999
- Jurisdiction ALDERLEY EDGE, CHESHIRE, ENGLAND
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Gentronix
Gentronix offers a comprehensive portfolio of products and services, including Genetic Toxicology Testing, GLP Genotoxicity Services, Skin Toxicology Services, and Flow Cytometry Services.
Screens for genotoxic hazards in chemicals using rapid assays.
Conducts GLP-compliant studies for gene mutation and safety.
Assesses skin irritation and sensitisation potential in vitro.
Delivers endpoints for toxicological hazard identification.
People of Gentronix
Unlock access to complete
Unlock access to complete
Funding Insights of Gentronix
Gentronix has successfully raised a total of $3.84M across 3 strategic funding rounds. The most recent funding activity was a Unspecified round of $938.37 thousand completed in November 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Gentronix
Gentronix has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Mercia, Scantox and NVM Private Equity.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments are managed across the UK.
|
Locked | Locked | Locked | |
|
Investment management services are provided by Mercia to various clients.
|
Locked | Locked | Locked | |
|
Laboratory focused on providing pharmacology, toxicology, and histopathology services
|
Locked | Locked | Locked |
Investor details for Gentronix
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Gentronix
Investment portfolio details for Gentronix
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Gentronix
Detailed financials for Gentronix
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Gentronix Comparisons
Peer comparison for Gentronix
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Gentronix
Gentronix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jade Bioscience, Tigermed, Shanghai Yaocheng Health Technology, ReveraGen and Aquila BioMedical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provides toxicology, chemistry, and consultancy services for agrochemical industries.
|
|
| Locked | Locked | Locked |
Drug development and preclinical services are provided by Tigermed.
|
|
| Locked | Locked | Locked |
Clinical trial services to biopharma sector are provided.
|
|
| Locked | Locked | Locked |
Steroids for Duchenne muscular dystrophy treatment are developed.
|
|
| Locked | Locked | Locked |
Preclinical services in immunology, regeneration, neuroscience, and histology are provided.
|
Detailed competitors of Gentronix
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Gentronix
Complete news archive for Gentronix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Gentronix
Gentronix was founded in 1999 and raised its 1st funding round 8 years after it was founded.
Gentronix is headquartered in Alderley Edge, United Kingdom. It is registered at Alderley Edge, Cheshire, United Kingdom.
Gentronix is a funded company, having raised a total of $3.84M across 3 funding rounds to date.
As of Dec 31, 2015, the latest employee count at Gentronix is 1.
Gentronix provides services and solutions to help organisations optimise the development of drugs and other chemicals, by reducing attrition due to toxicity thus ensuring safer products across a wide range of chemistry driven industries. Provide contract services for genotoxicity using patented human cell GADD45a reporter, GreenScreen HC and BlueScreen HC assays and related assays including Micronucleus and Ames MPF. Offerings include - GreenScreen HC, BlueScreen HC, Ames MPF, Ames bacterial reverse mutation assay (OECD 471 ), In Vitro Mammalian Cell Micronucleus Test (OECD 487), MicroFlow Micronucleus Test, Micronucleus Test in vivo, Comet Assay, H2AX by Flow Cytometry, Apoptosis Suite, Flow Cytometry Services and Predictive Toxicology Services. Serves - Pharmaceutical Industry, Chemical Industry, Agrochemical, Fragrances and Flavours, Personal Care Products, Consumer Products, Biomaterials, Biomedical Devices and Contract Research Organisations.
Gentronix's top competitors include PHAXIAM, BioQual and Jade Bioscience.
Gentronix offers Genetic Toxicology Testing, GLP Genotoxicity Services, Skin Toxicology Services, and Flow Cytometry Services.
Gentronix has 3 investors. Key investors include Mercia, Scantox, and NVM Private Equity.